Decoding Disease:
Advanced Signal Processing for
Early Diagnosis
Discover OTraces, where breakthrough technology meets critical healthcare innovation.
Our platform uses advanced signal processing and machine learning to revolutionize early disease detection, offering unprecedented diagnostic precision.
Technology for 95%+ Accuracy:
Your Ideal Co-Development Partner
OTraces offers a diagnostic platform achieving 95% accuracy, making us the ideal co-development partner for building highly accurate diagnostic tests for any indication. Our advanced signal processing and multidimensional spatial analysis enhance biomarker clarity and data relevance, while our powerful machine learning algorithms detect subtle patterns missed by traditional methods. This combination ensures high precision across various medical indications, from cancer to chronic diseases. By partnering with OTraces, researchers, therapeutic drug and diagnostic test developers gain access to our proven technology and collaborative development support, enabling the creation of reliable, innovative diagnostic solutions that drive advancements in medical research and patient care.
About OTraces
At OTraces, we leverage advanced signal processing and machine learning technologies to enhance early disease detection using sophisticated data analysis techniques to refine raw biomarker data and develop accurate biological signatures. This capability allows for the early and precise detection of a wide range of diseases, supporting significant advancements in therapeutic drug development and diagnostic outcomes.
In cancer diagnostics, our unique approach detects changes in the tumor microenvironment by measuring changes to cytokines and proteins in response to cancer, providing unparalleled accuracy in cancer detection.
Why OTraces?
Empowering Research with Precision Analytics
TAILORED DIAGNOSTIC SOLUTIONS
TAILORED DIAGNOSTIC SOLUTIONS
From cancer to chronic diseases, our customizable diagnostic ML algorithms are designed to meet specific diagnostic needs.
ADVANCED DIAGNOSTIC SUPPORT
ADVANCED DIAGNOSTIC SUPPORT
We partner with diagnostic providers to integrate our tools seamlessly into their existing workflows, offering expertise sharing and scalable solutions that grow with demands.
INNOVATIVE TECHNOLOGY
INNOVATIVE TECHNOLOGY
Our core technologies, including advanced signal processing and multidimensional spatial analysis, allow researchers and providers to analyze complex biological data with unparalleled precision.
EXCEPTIONAL CANCER DETECTION
EXCEPTIONAL CANCER DETECTION
Our technology detects changes in the tumor microenvironment by measuring changes to cytokines and proteins in response to cancer, providing highly accurate and early cancer detection, which can significantly improve research programs and patient outcomes.
Our Mission
Empowering early detection and intervention, we transform disease diagnostics by equipping providers and researchers with state-of-the-art tools necessary for the early detection of diseases. This crucial insight enables the development of timely and effective therapeutic interventions, significantly enhancing patient outcomes. By fulfilling this urgent healthcare need, we advance medical research, fulfill the growing global demand for effective, efficient, diagnostic tools, as well as address the growing concerns of health equity.
Our Mission
Empowering early detection and intervention, we transform disease diagnostics by equipping providers and researchers with state-of-the-art tools necessary for the early detection of diseases. This crucial insight enables the development of timely and effective therapeutic interventions, significantly enhancing patient outcomes. By fulfilling this urgent healthcare need, we advance medical research, fulfill the growing global demand for effective, efficient, diagnostic tools, as well as address the growing concerns of health equity.
Featured Solutions
Customizable Tools for Diverse Diagnostic Needs
Disease-Specific Tools
Targeted solutions for various diseases, enhancing early detection and facilitating effective diagnosis and research into new treatments.
Prostate Cancer Test
Accuracy 98.6% >
Predictive Analytics
Our models predict disease progression, offering researchers valuable insights for preventive and intervention strategies.
Biomarker Behavor in the TME for Breast Cancer by Stage
Testimonials
Here’s what our collaborators have to say about their experiences with OTraces technology.
The OTraces platform is a unique cancer detection test because it detects the changes in the microenvironment of the tumor rather than changes in the tumor cells themselves. These changes are detected by measuring cytokines and proteins released by the cancer cells and the patients’ own cells in response to the presence of cancer and using proprietary algorithms to detect the presence of cancer. To my knowledge, no other platform / diagnostic test uses this approach to detect cancer. The preliminary data demonstrates exemplary accuracy in detecting the presence of cancer.
Kenneth Pienta, MD is the Donald S. Coffey professor of urology and is a professor of oncology, pharmacology and molecular sciences at the Johns Hopkins University School of Medicine. He also serves as director of the The Brady Urological Institute. Dr. Pienta’s research considers the ecology of cancer, tumor microenvironment, metastasis, biomarker development, novel therapeutic development, the concept that cancer tumorigenesis and metastasis can best be addressed utilizing the principles of ecology as related to invasive species and developing new treatments for cancer through network disruption. He is the author of more than 350 peer-reviewed articles. Dr. Pienta received his BS in 1983 and his M.D in 1986, both from Johns Hopkins University.
Having treated cancer patients for 40 years, during which huge progress has been made in breast cancer treatment and survival – the most critical aspect of cancer treatment is the earliest possible diagnosis (when the sub clonal driving genomic populations are the simplest) and to treat each and every genomic population extremely aggressively. This leads to the highest possible cure rate. Hence, in order to detect cancer at the earliest possible stage, one needs to focus completely on the tumor microenvironment. This is where Otraces technology has delivered monumental results where others—focused on ctDNA—have failed. For ctDNA cannot detect early tumors until the original cancer is 1cm in diameter. OTraces has proven results – having run over 1,500 breast cancer samples through its diagnostic test development and blind validation process with > 96% predictive power. To my knowledge, no other technology delivers such game-changing outcomes.
Dr. Brian Leyland-Jones, BSc (1st Class Hons), MB, BS, PhD, FACP, FRCPC, Chief Medical Officer of the National Foundation of Cancer Research (not-for-profit)
Testimonials
Here’s what our collaborators have to say about their experiences with OTraces technology.
The OTraces platform is a unique cancer detection test because it detects the changes in the microenvironment of the tumor rather than changes in the tumor cells themselves. These changes are detected by measuring cytokines and proteins released by the cancer cells and the patients’ own cells in response to the presence of cancer and using proprietary algorithms to detect the presence of cancer. To my knowledge, no other platform / diagnostic test uses this approach to detect cancer. The preliminary data demonstrates exemplary accuracy in detecting the presence of cancer.
Kenneth Pienta, MD is the Donald S. Coffey professor of urology and is a professor of oncology, pharmacology and molecular sciences at the Johns Hopkins University School of Medicine. He also serves as director of the The Brady Urological Institute. Dr. Pienta’s research considers the ecology of cancer, tumor microenvironment, metastasis, biomarker development, novel therapeutic development, the concept that cancer tumorigenesis and metastasis can best be addressed utilizing the principles of ecology as related to invasive species and developing new treatments for cancer through network disruption. He is the author of more than 350 peer-reviewed articles. Dr. Pienta received his BS in 1983 and his M.D in 1986, both from Johns Hopkins University.
Having treated cancer patients for 40 years, during which huge progress has been made in breast cancer treatment and survival—the most critical aspect of cancer treatment is the earliest possible diagnosis (when the sub clonal driving genomic populations are the simplest) and to treat each and every genomic population extremely aggressively. This leads to the highest possible cure rate. Hence, in order to detect cancer at the earliest possible stage, one needs to focus completely on the tumor microenvironment. This is where Otraces technology has delivered monumental results where others—focused on ctDNA—have failed. For ctDNA cannot detect early tumors until the original cancer is 1cm in diameter. OTraces has proven results—having run over 1,500 breast cancer samples through its diagnostic test development and blind validation process with >96% predictive power. To my knowledge, no other technology delivers such game-changing outcomes.
Dr. Brian Leyland-Jones, BSc (1st Class Hons), MB, BS, PhD, FACP, FRCPC, Chief Medical Officer of the National Foundation of Cancer Research (not-for-profit)
